spacer
home > ebr > autumn 2017 > invaluable influences
PUBLICATIONS
European Biopharmaceutical Review

Invaluable Influences

The global prescription drug sales are forecast to grow robustly at 6.5% for the next five years, thus reaching $1.06 trillion in 2022 (1). However, it remains an increasing challenge to achieve FDA approval for a new drug application in an industry that runs high on failure rates. Figure 1 illustrates the number of FDA drug approvals from 1995 to 2016. After a high in the mid-to-late 90s, the number of drug approvals somewhat stagnated at around 23 per annum for a decade, before recovering more latterly.

Attrition in the pharmaceutical industry remains high at approximately 90% from Phase 1 through to launch of a novel drug (2). This is on the back of significantly higher attrition in the research phase. Typically 200-500 compounds are made during drug discovery, yet only one of these, synthesised in an iterative manner, will be nominated as the drug candidate. R&D spending has spiralled in recent years and has not resulted in more success.

In 2000, it typically cost approximately $1 billion to develop a new drug, versus $2.6 billion in 2015 (3). This misbalance of the books led to the dramatic change in the way that drugs are discovered and developed from traditionally pharma-in-house to often fully outsourced models, the consequence of which is the global shrinking of pharma sites and staff. Additionally, large pharma are increasingly active in acquisitions of biotechnology organisations and smaller firms to bolster their pipelines. Therefore, for the biotechs, reliance on capabilities, expertise and advice from the CRO sector is growing significantly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Richard Weaver FRSC is the Managing Director of XenoGesis Ltd, a rapidly growing CRO based in BioCity Nottingham, UK. Having joined Astra Charnwood in 1997 within Discovery DMPK, he progressed to Group and Project Leader at AstraZeneca. Richard gained a first class honours degree in chemistry, with awards for the best performance in every year, followed by a medicinal chemistry PhD with a Wellcome Trust scholarship at the University of Leicester, UK, and two subsequent postdoctoral positions at the Welsh School of Pharmacy, Wales.
spacer
Dr Richard Weaver
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Three-tiered, mobile-app driven program tracks individuals’ physical and psychological symptoms from COVID-19

RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement